Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.

E. G. Quetglas, A. Armuzzi, S. Wigge, G. Fiorino, L. Barnscheid, M. Froelich, Silvio Danese, Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment European Journal of Clinical Pharmacology. ,vol. 71, pp. 773- 799 ,(2015) , 10.1007/S00228-015-1862-7

Antje Timmer, Petrease H Patton, Nilesh Chande, John WD McDonald, John K MacDonald, Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis Cochrane Database of Systematic Reviews. ,(2016) , 10.1002/14651858.CD000478.PUB4

David S. Kotlyar, James D. Lewis, Laurent Beaugerie, Ann Tierney, Colleen M. Brensinger, Javier P. Gisbert, Edward V. Loftus, Laurent Peyrin-Biroulet, Wojciech C. Blonski, Manuel Van Domselaar, Maria Chaparro, Sandipani Sandilya, Meenakshi Bewtra, Florian Beigel, Livia Biancone, Gary R. Lichtenstein, Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clinical Gastroenterology and Hepatology. ,vol. 13, pp. 847- 858 ,(2015) , 10.1016/J.CGH.2014.05.015

Nabeel Khan, Ali M. Abbas, Gary R. Lichtenstein, Edward V. Loftus, Lydia A. Bazzano, Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. ,vol. 145, pp. 1007- 1015 ,(2013) , 10.1053/J.GASTRO.2013.07.035

William J. Sandborn, Gert van Assche, Walter Reinisch, Jean–Frederic Colombel, Geert D'Haens, Douglas C. Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B. Thakkar, Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology. ,vol. 142, pp. 257- 265 ,(2012) , 10.1053/J.GASTRO.2011.10.032

W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle, J Li, P F Pollack, Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial Gut. ,vol. 56, pp. 1232- 1239 ,(2007) , 10.1136/GUT.2006.106781

Marine Camus, Philippe Seksik, Anne Bourrier, Isabelle Nion–Larmurier, Harry Sokol, Philippe Baumer, Laurent Beaugerie, Jacques Cosnes, Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clinical Gastroenterology and Hepatology. ,vol. 11, pp. 389- 394 ,(2013) , 10.1016/J.CGH.2012.10.038

Mirthe Emilie van der Valk, Marie-Josée J Mangen, Max Leenders, Gerard Dijkstra, Ad A van Bodegraven, Herma H Fidder, Dirk J de Jong, Marieke Pierik, C Janneke van der Woude, Mariëlle JL Romberg-Camps, Cees HM Clemens, Jeroen M Jansen, Nofel Mahmmod, Paul C van de Meeberg, Andrea E van der Meulen-de, Cyriel Y Ponsioen, Clemens JM Bolwerk, J Reinoud Vermeijden, Peter D Siersema, Martijn GH van Oijen, Bas Oldenburg, COIN Study Group, Dutch Initiative on Crohn and Colitis, Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Gut. ,vol. 63, pp. 72- 79 ,(2014) , 10.1136/GUTJNL-2012-303376

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel Present, Bruce E. Sands, Jean Frédéric Colombel, Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis The New England Journal of Medicine. ,vol. 353, pp. 2462- 2476 ,(2005) , 10.1056/NEJMOA050516

Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao, Paul Rutgeerts, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial The Lancet. ,vol. 359, pp. 1541- 1549 ,(2002) , 10.1016/S0140-6736(02)08512-4